Paul R. Rhomberg mainly focuses on Microbiology, Ceftazidime, Meropenem, Antibiotic resistance and Cefepime. His Enterobacteriaceae research extends to the thematically linked field of Microbiology. His Ceftazidime research focuses on Cephalosporin and how it connects with Cefpirome, Salmonella, Ceftolozane, Bacteroides fragilis and Piperacillin/tazobactam.
His research in Antibiotic resistance intersects with topics in Penicillin, Ciprofloxacin, Group B Streptococcal Infection and Drug resistance. His studies in Cefepime integrate themes in fields like Piperacillin and Tazobactam. His Antibacterial agent research is multidisciplinary, incorporating perspectives in Moxifloxacin, Daptomycin and Streptococcus pneumoniae.
His primary scientific interests are in Microbiology, Broth microdilution, Antimicrobial, Staphylococcus aureus and Meropenem. His research related to Antibacterial agent, Carbapenem, Streptococcus pneumoniae, Tazobactam and Imipenem might be considered part of Microbiology. His Streptococcus pneumoniae research focuses on Haemophilus influenzae and how it relates to Virology.
His Broth microdilution research also works with subjects such as
His primary areas of study are Microbiology, Broth microdilution, Antimicrobial, Sentry and Klebsiella pneumoniae. His study in Microbiology is interdisciplinary in nature, drawing from both Gram, Tedizolid and Staphylococcus aureus. He has researched Broth microdilution in several fields, including Enterobacterales and Colistin.
The Antimicrobial study combines topics in areas such as Pseudomonas aeruginosa and Tebipenem. Paul R. Rhomberg interconnects Long acting, Antifungal, Clinical trial and Echinocandin in the investigation of issues within Sentry. The study incorporates disciplines such as Carbapenem, Meropenem, Imipenem, Proteus mirabilis and Enterobacteriaceae in addition to Klebsiella pneumoniae.
His scientific interests lie mostly in Microbiology, Staphylococcus aureus, Fosfomycin, Candida glabrata and Candida tropicalis. Many of his studies involve connections with topics such as Klebsiella pneumoniae and Microbiology. His Klebsiella pneumoniae research incorporates themes from Pseudomonas aeruginosa, Broth microdilution, Enterobacteriaceae and Acinetobacter.
His Candida glabrata study incorporates themes from Candida parapsilosis, Candida dubliniensis and Candida krusei. His study in Clindamycin is interdisciplinary in nature, drawing from both Methicillin-resistant Staphylococcus aureus and Tedizolid. Paul R. Rhomberg has researched Resistant bacteria in several fields, including Enterobacterales and Sentry.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in the United States during 1999–2000, Including a Comparison of Resistance Rates since 1994–1995
Gary V. Doern;Kristopher P. Heilmann;Holly K. Huynh;Paul R. Rhomberg.
Antimicrobial Agents and Chemotherapy (2001)
Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
Paul R. Rhomberg;Ronald N. Jones.
Diagnostic Microbiology and Infectious Disease (2009)
Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995
Angela B. Brueggemann;Stacy L. Coffman;Paul Rhomberg;Holly Huynh.
Antimicrobial Agents and Chemotherapy (2002)
Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005).
Lalitagauri M. Deshpande;Paul R. Rhomberg;Helio S. Sader;Ronald N. Jones.
Diagnostic Microbiology and Infectious Disease (2006)
Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
Helio S. Sader;Paul R. Rhomberg;David J. Farrell;Ronald N. Jones.
Antimicrobial Agents and Chemotherapy (2011)
In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
Akinobu Ito;Naoki Kohira;Samuel K. Bouchillon;Joshua West.
Journal of Antimicrobial Chemotherapy (2016)
Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere.
Janet I. Andrews;Daniel J. Diekema;Stephen K. Hunter;Paul R. Rhomberg.
American Journal of Obstetrics and Gynecology (2000)
Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999–2001)
Alan H. Mutnick;Paul R. Rhomberg;Helio S. Sader;Ronald N. Jones.
Journal of Antimicrobial Chemotherapy (2004)
Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae
Mariana Castanheira;Paul R. Rhomberg;Robert K. Flamm;Ronald N. Jones.
Antimicrobial Agents and Chemotherapy (2016)
Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).
Mariana Castanheira;Shawn A. Messer;Paul R. Rhomberg;Michael A. Pfaller.
Diagnostic Microbiology and Infectious Disease (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: